Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDXNASDAQ:INVANASDAQ:MNKDNASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$19.54-0.7%$18.87$14.40▼$47.00$1.29B1.33915,393 shs301,280 shsINVAInnoviva$21.15+1.3%$18.48$15.56▼$21.28$1.33B0.37655,822 shs662,979 shsMNKDMannKind$4.31-1.0%$4.59$4.05▼$7.63$1.31B1.142.37 million shs690,244 shsVSTMVerastem$6.13-0.6%$6.58$2.10▼$9.10$337.11M0.851.13 million shs869,711 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics-1.01%+5.41%-3.06%-7.78%-39.96%INVAInnoviva+1.36%+9.21%+11.42%+18.70%+30.99%MNKDMannKind-1.58%+6.88%-12.30%-11.59%-4.40%VSTMVerastem+4.58%-18.92%-11.98%-11.35%+67.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics1.7848 of 5 stars4.50.00.00.02.70.00.0INVAInnoviva4.4126 of 5 stars3.51.00.04.23.12.51.9MNKDMannKind2.9589 of 5 stars3.61.00.00.02.91.71.9VSTMVerastem2.838 of 5 stars4.50.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.90Moderate Buy$53.90175.84% UpsideINVAInnoviva 3.00Buy$55.00160.11% UpsideMNKDMannKind 3.25Buy$10.00132.29% UpsideVSTMVerastem 3.00Buy$13.63122.27% UpsideCurrent Analyst Ratings BreakdownLatest VSTM, CLDX, MNKD, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.005/9/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.005/9/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.005/9/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $14.005/6/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/28/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$64.004/10/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.004/10/2025VSTMVerastemJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/9/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/9/2025VSTMVerastemMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.003/24/2025VSTMVerastemGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $14.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.56M171.60N/AN/A$9.08 per share2.15INVAInnoviva$369.84M3.59$4.09 per share5.17$10.66 per share1.98MNKDMannKind$297.60M4.40N/AN/A($0.91) per share-4.73VSTMVerastem$10M33.68N/AN/A$2.27 per share2.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$141.43M-$2.70N/AN/AN/A-1,544.32%-19.75%-18.86%8/14/2025 (Estimated)INVAInnoviva$179.72M-$1.0130.6513.64N/A18.31%20.84%11.38%7/29/2025 (Estimated)MNKDMannKind-$11.94M$0.1061.5018.72N/A8.07%-17.74%8.68%8/6/2025 (Estimated)VSTMVerastem-$87.37M-$3.20N/AN/AN/AN/A-332.73%-73.97%8/14/2025 (Estimated)Latest VSTM, CLDX, MNKD, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025VSTMVerastem-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million3/20/2025Q4 2024VSTMVerastem-$0.76-$1.33-$0.57-$1.33$0.15 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A24.2724.27INVAInnoviva0.381.791.64MNKDMannKindN/A4.544.17VSTMVerastem2.773.233.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AINVAInnoviva99.12%MNKDMannKind49.55%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics3.80%INVAInnoviva2.25%MNKDMannKind2.70%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.82 millionOptionableINVAInnoviva10062.78 million61.54 millionOptionableMNKDMannKind400303.93 million267.51 millionOptionableVSTMVerastem5054.95 million43.53 millionOptionableVSTM, CLDX, MNKD, and INVA HeadlinesRecent News About These CompaniesVerastem reports promising cancer drug trial resultsJune 4 at 12:37 AM | investing.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) InhibitorJune 4 at 12:37 AM | businesswire.comVerastem’s Promising Clinical Advances and Strategic Developments Justify Buy RatingJune 3 at 6:32 AM | tipranks.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Buy" from BrokeragesJune 3 at 1:33 AM | marketbeat.comVerastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns BullishJune 2 at 7:01 PM | msn.comVerastem Announces Strategic Plans in Investor WebcastJune 2 at 12:58 PM | tipranks.comWhat's Going On With Verastem Oncology Stock On Monday?June 2 at 12:58 PM | benzinga.comVerastem, Inc. (NASDAQ:VSTM) Short Interest UpdateJune 2 at 10:13 AM | marketbeat.comVerastem Announces Promising Phase 1 Study ResultsJune 2 at 10:13 AM | tipranks.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) InhibitorJune 2 at 9:40 AM | businesswire.comInvestors Buy Large Volume of Verastem Call Options (NASDAQ:VSTM)May 31, 2025 | marketbeat.comVSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug ApprovalMay 28, 2025 | zacks.comVerastem Oncology to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | businesswire.comNorthern Trust Corp Boosts Holdings in Verastem, Inc. (NASDAQ:VSTM)May 28, 2025 | marketbeat.com723,806 Shares in Verastem, Inc. (NASDAQ:VSTM) Bought by Woodline Partners LPMay 27, 2025 | marketbeat.comBNP Paribas Financial Markets Makes New $387,000 Investment in Verastem, Inc. (NASDAQ:VSTM)May 27, 2025 | marketbeat.comVerastem’s SWOT analysis: biotech firm’s stock poised for growth amid challengesMay 23, 2025 | investing.comVerastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline ...May 23, 2025 | finance.yahoo.comVerastem expands ambitions with strong pancreatic cancer data at ASCOMay 23, 2025 | thepharmaletter.comVerastem announces positive Phase 1/2 safety and efficacy results in PDACMay 23, 2025 | finance.yahoo.comVerastem Announces Positive RAMP 205 Trial ResultsMay 23, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVSTM, CLDX, MNKD, and INVA Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$19.54 -0.13 (-0.66%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Innoviva NASDAQ:INVA$21.14 +0.27 (+1.27%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.MannKind NASDAQ:MNKD$4.30 -0.05 (-1.03%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Verastem NASDAQ:VSTM$6.13 -0.04 (-0.65%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
